摘要
目的分析抗肿瘤药物配置与输注环节的时效风险,优化静脉用药调配中心(PIVAS)工作流程,提升药物治疗安全性。方法基于某院PIVAS 2024年9~12月闭环管理系统的全链路追溯数据,统计分析抗肿瘤药物配置稀释液稳定性超时限率及输注时限达标率并提出改进建议。结果在30670条配置记录中,稀释液超时率为10.78%(3306例),集中于稳定性≤6 h的洛铂、美法仑等药物;22474条输注记录中,34.59%(7773例)输注时限未达标,高发于长春瑞滨、吉西他滨等药物。结论基于全链路时间追溯数据,针对高时效性风险的抗肿瘤药物,通过配置排程优化、冷链贮存强化及输注辅助系统开发,提升临床用药的安全性。
OBJECTIVE To analyze the time-sensitive risks involved in the preparation and infusion processes of antineoplastic drugs,optimize the workflow of the Intravenous Admixture Service(PIVAS),and enhance the safety of pharmacotherapy.METHODS Based on whole-process traceability data from the closed-loop management system of a hospital's PIVAS during September to December 2024,statistical analysis was conducted on the over-time rate of antitumor drug diluent stability and the compliance rate of infusion time limits,with improvement recommendations proposed.RESULTS Among 30670 preparation records,the diluent stability overtime rate was 10.78%(3306 cases),primarily involving drugs with stability≤6 hours such as Lobaplatin and Melphalan.In 22474 infusion records,34.59%(7773 cases)did not meet the infusion deadline,most frequently seen with Vinorelbine and Gemcit-abine.CONCLUSION Based on comprehensive timeline traceability data,recommendations are made to enhance the clinical safety of high time-sensitive risk antineoplastic drugs by optimizing scheduling,strengthening cold chain storage,and developing auxiliary infusion systems.
作者
郑铭杰
郑碧容
林文强
ZHENG Ming-jie;ZHENG Bi-rong;LIN Wen-qiang(Department of Pharmacy,Fujian Medical University Union Hospital,Fuzhou 350001,China)
出处
《海峡药学》
2025年第12期160-163,共4页
Strait Pharmaceutical Journal
关键词
智能化闭环管理
抗肿瘤药物
稀释液稳定性
输注时限
Intelligent Closed-Loop Management
Antineoplastic Drugs
Diluent Stability
Infusion Deadline
